

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07D 211/62, A61K 31/445, C07D 401/06, 405/04, 409/04</b>		A1	(11) International Publication Number: <b>WO 00/39092</b>
			(43) International Publication Date: 6 July 2000 (06.07.00)
(21) International Application Number: <b>PCT/US99/29834</b> (22) International Filing Date: 15 December 1999 (15.12.99) (30) Priority Data: 60/113,595                      24 December 1998 (24.12.98)      US (71) Applicant (for all designated States except US): <b>ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>KLIMKOWSKI, Valentine, Joseph [US/US]; 4504 Camelot Lane, Carmel, IN 46033 (US). KYLE, Jeffrey, Alan [US/US]; 10434 Collingswood Lane, Fishers, IN 46038 (US). MASTERS, John, Joseph [US/US]; 12047 Flint Stone Court, Fishers, IN 46038 (US). WILEY, Michael, Robert [US/US]; 7725 Langwood Drive, Indianapolis, IN 46268 (US).</b> (74) Agents: <b>JACKSON, Thomas, E. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: <b>HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR Xa</b>			
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <math display="block">Q^1 - L^1 - \overset{\overset{O}{\parallel}}{S} - N \text{---} \text{piperidine ring} \text{---} N - CO - Q^2 \quad (I)</math> </div> <div style="text-align: center;"> <math display="block">-(CO) - \text{cyclohexane ring} - N - R \quad (a)</math> </div> </div>			
(57) Abstract  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) wherein: Q <sup>1</sup> is phenyl or 2-naphthalenyl either of which may bear one or more halo, trifluoromethyl, methoxy or methyl substituents; L <sup>1</sup> is a direct bond, methylene, ethylene or ethen-1, 2-diyl; and Q <sup>2</sup> is Q <sup>2A</sup> , Q <sup>2B</sup> , or Q <sup>2C</sup> in which Q <sup>2A</sup> (showing the CO to which it is attached) is of formula (a) in which each of m and n independently is 0 or 1; Q <sup>2B</sup> is 1-piperazinyl which bears at the 4-position the group R; Q <sup>2C</sup> is 3,4-didehydropiperidin-4-yl which bears at the 1-position the group R; pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR Xa

5

This application claims the benefit of U.S. Provisional Application No. 60/113,595, filed 24 December 1998.

This invention relates to antithrombotic heterocyclic amides which demonstrate activity as inhibitors of factor Xa and, accordingly, which are useful anticoagulants in mammals. In particular it relates to heterocyclic amides having high anticoagulant activity, and antithrombotic activity. Thus, this invention relates to new amides which are inhibitors of factor Xa, pharmaceutical compositions containing the amides as active ingredients, and the use of the amides as anticoagulants for prophylaxis and treatment of thromboembolic disorders such as venous thrombosis, pulmonary embolism, arterial thrombosis, in particular myocardial ischemia, myocardial infarction and cerebral thrombosis, general hypercoagulable states and local hypercoagulable states, such as following angioplasty and coronary bypass operations, and generalized tissue injury as it relates to the inflammatory process. In addition, the antithrombotic agents are useful as anticoagulants in *in vitro* applications.

The process of blood coagulation, thrombosis, is triggered by a complex proteolytic cascade leading to the formation of thrombin. Thrombin proteolytically removes activation peptides from the A $\alpha$ -chains and the B $\beta$ -chains of fibrinogen, which is soluble in blood plasma, initiating insoluble fibrin formation. The formation of thrombin from prothrombin is catalyzed by factor Xa.

- 2 -

Anticoagulation currently is achieved by the administration of heparins and coumarins. Parenteral pharmacological control of coagulation and thrombosis is based on inhibition of thrombin through the use of heparins.

5 Heparins act indirectly on thrombin by accelerating the inhibitory effect of endogenous antithrombin III (the main physiological inhibitor of thrombin). Because antithrombin III levels vary in plasma and because clot-bound thrombin seems resistant to this indirect mechanism, heparins can be

10 an ineffective treatment. Because coagulation assays are believed to be associated with efficacy and with safety, heparin levels must be monitored with coagulation assays (particularly the activated partial thromboplastin time (APTT) assay). Coumarins impede the generation of thrombin

15 by blocking the posttranslational gamma-carboxylation in the synthesis of prothrombin and other proteins of this type. Because of their mechanism of action, the effect of coumarins can only develop slowly, 6-24 hours after administration. Further, they are not selective

20 anticoagulants. Coumarins also require monitoring with coagulation assays (particularly the prothrombin time (PT) assay).

Recently, interest has grown in small synthetic molecules which demonstrate potent direct inhibition of

25 thrombin and factor Xa. See, Joseph P. Vacca (Annette M. Doherty Section Editor), Annual Reports in Medicinal Chemistry, (1998), 33, 81-90, as well as WO 96/10022.


Although the heparins and coumarins are effective anticoagulants, there still exists a need for anticoagulants

30 which act selectively on factor Xa or thrombin, and which, independent of antithrombin III, exert inhibitory action shortly after administration, preferably by an oral route, and do not interfere with lysis of blood clots, as required to maintain hemostasis.

- 3 -

The present invention is directed to the discovery that the amides of the present invention, as defined below, are potent inhibitors of factor Xa which may have high bioavailability following oral administration.

5 According to the invention there is provided a compound of formula I




10 (or a pharmaceutically acceptable salt thereof) wherein:

$Q^1$  is phenyl or 2-naphthalenyl either of which may bear one or more halo, trifluoromethyl, methoxy or methyl substituents;

$L^1$  is a direct bond, methylene, ethylene or ethen-1,2-diyl; and

15  $Q^2$  is  $Q^{2A}$ ,  $Q^{2B}$ , or  $Q^{2C}$  in which

$Q^{2A}$  (showing the CO to which it is attached) is



20

in which each of m and n independently is 0 or 1;


$Q^{2B}$  is 1-piperazinyl which bears at the 4-position the group R; and

$Q^{2C}$  is 3,4-didehydropiperidin-4-yl which bears at the 1-position the group R; and

25 R is t-butyl,  $-CHRYR^Z$ , or  $-CHR^WR^X$  wherein

each of  $R^W$  and  $R^X$  independently is hydrogen or (1-3C)normal alkyl, or  $-CHR^WR^X$  is 2-indanyl or (showing the nitrogen to which it is attached) is

- 4 -



in which T is a single bond or methylene and U is methylene,  
5 ethylene, oxy,  $-S(O)_q-$  (wherein q is 0, 1 or 2) or imino  
(which may bear a methyl substituent), or T is  
ethan-1,1-diyl and U is a single bond or methylene;

RY is hydrogen or methyl; and

R<sup>2</sup> is isopropyl, t-butyl, (3-6C)cycloalkyl, phenyl  
10 (which is unsubstituted or bears one or more substituents  
independently selected from halo, methyl, methoxy and  
hydroxy), 4-quinolinyl or heteroaryl (which heteroaryl is a  
5-membered aromatic ring which includes one to four  
heteroatoms selected from sulfur, oxygen and nitrogen or is  
15 a 6-membered aromatic ring which includes one to three  
nitrogen atoms, wherein the heteroaryl is attached at carbon  
and may bear one or more methyl substituents on carbon or  
nitrogen).

As used herein, the expression a compound of formula I  
20 or the expression a compound of the invention includes the  
compound and any conventional prodrug thereof, as well as a  
pharmaceutically acceptable salt of said compound or  
prodrug.

A particular compound of formula I is one wherein  
25 Q<sup>1</sup> is phenyl or 2-naphthalenyl either of which may bear  
a chloro substituent;

L<sup>1</sup> is a direct bond or trans-ethen-1,2-diyl; and

Q<sup>2</sup> is Q<sup>2A</sup>, Q<sup>2B</sup>, or Q<sup>2C</sup> in which


Q<sup>2A</sup> is 4-piperidinyl which bears at the 1-position the  
30 group R;

- 5 -

$Q^{2B}$  is 1-piperazinyl which bears at the 4-position the group R; and

$Q^{2C}$  is 3,4-didehydropiperidin-4-yl which bears at the 1-position the group R;

- 5        R is  $-CHRYR^Z$  or  $-CHR^WR^X$  wherein  
          each of  $R^W$  and  $R^X$  independently is hydrogen or  
          (1-3C)normal alkyl; or  $-CHR^WR^X$  is 2-indanyl or (showing the  
          nitrogen to which it is attached) is



10

- in which T is a single bond or methylene and U is methylene,  
          ethylene, oxy,  $-S(O)_q-$  (wherein q is 0, 1 or 2) or imino  
          (which may bear a methyl substituent), or T is  
 15        ethan-1,1-diyl and U is a single bond or methylene;

$RY$  is hydrogen or methyl; and

- $R^Z$  is isopropyl, t-butyl, (3-6C)cycloalkyl, phenyl  
          (which is unsubstituted or bears one or more substituents  
          independently selected from halo, methyl, methoxy and  
 20        hydroxy), 4-quinolinyl or heteroaryl (which heteroaryl is a  
          5-membered aromatic ring which includes one to four  
          heteroatoms selected from sulfur, oxygen and nitrogen or is  
          a 6-membered aromatic ring which includes one to three  
          nitrogen atoms, wherein the heteroaryl is attached at carbon  
 25        and may bear one or more methyl substituents on carbon or  
          nitrogen).

- A pharmaceutically acceptable salt of an antithrombotic  
          agent of the instant invention includes one which is an  
          acid-addition salt made from a basic compound of formula I  
 30        and an acid which provides a pharmaceutically acceptable  
          anion. Thus, a salt of a novel compound of formula I as

- 6 -

provided herein made with an acid which affords a pharmaceutically acceptable counterion provides a particular aspect of the invention. Examples of such acids and bases are provided hereinbelow.

5       As an additional aspect of the invention there is provided a pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier, diluent or excipient, a novel compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in any  
10 of the descriptions herein.

      In addition, there is provided the use of a factor Xa inhibiting compound of formula I (or prodrug or salt) as described herein as an active ingredient in the manufacture of a medicament for use in producing an anticoagulant or  
15 antithrombotic effect.

      The present invention also provides a method of inhibiting coagulation in a mammal comprising administering to a mammal in need of treatment, a coagulation inhibiting dose of a factor Xa inhibiting compound of formula I having  
20 any of the definitions herein.

      The present invention further provides a method of inhibiting factor Xa comprising administering to a mammal in need of treatment, a factor Xa inhibiting dose of a factor Xa inhibiting compound of formula I having any of the  
25 definitions herein.

      Further, the present invention provides a method of treating a thromboembolic disorder comprising administering to a mammal in need of treatment, an effective dose of a factor Xa inhibiting compound of formula I having any of the  
30 definitions herein.

      In addition, there is provided the use of a factor Xa inhibiting compound of formula I having any of the definitions herein for the manufacture of a medicament for treatment of a thromboembolic disorder.



- 7 -

As an additional feature of the invention there is provided a pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier, diluent or excipient, a prodrug of a factor Xa inhibiting  
5 compound of formula I (or of a pharmaceutically acceptable salt thereof) as provided in any of the descriptions herein.

In this specification, the following definitions are used, unless otherwise described: Halo is fluoro, chloro, bromo or iodo. Alkyl, alkoxy, etc. denote both straight and  
10 branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain ("normal") radical, a branched chain isomer such as "isopropyl" being specifically denoted.

Particular values are listed below for radicals, substituents, and ranges, for illustration only, and they do  
15 not exclude other defined values or other values within defined ranges for the radicals and substituents.

For an alkyl group or the alkyl portion of an alkyl containing group such as, for example alkoxy, a particular  
20 value for (1-3C)normal alkyl is methyl, ethyl or propyl; and for (3-6C)cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. A particular value for halo is bromo or chloro, and more particularly is chloro.

A particular value for  $Q^1$  is 4-chlorophenyl or  
25 6-chloronaphthalen-2-yl. A particular value for  $-L^1-Q^1$  is 4-chloro-trans-styryl or 6-chloronaphthalen-2-yl. A particular value for  $Q^2$  is 1-isopropylpiperidin-4-yl, 1-cyclohexylpiperidin-4-yl, 4-isopropylpiperazin-1-yl, or 1-(tetrahydropyran-4-yl)piperidin-4-yl.

30 Particular species include those listed below in the examples.

It will be appreciated that certain compounds of formula I (or salts or prodrugs, etc.) may exist in, and be isolated in, isomeric forms, including tautomeric forms,

- 8 -

cis- or trans-isomers, as well as optically active, racemic, or diastereomeric forms. It is to be understood that the present invention encompasses a compound of formula I in any of the tautomeric forms or as an a mixture thereof; or as a  
5 mixture of diastereomers, as well as in the form of an individual diastereomer, and that the present invention encompasses a compound of formula I as a mixture of enantiomers, as well as in the form of an individual enantiomer, any of which mixtures or form possesses  
10 inhibitory properties against factor Xa, it being well known in the art how to prepare or isolate particular forms and how to determine inhibitory properties against factor Xa by standard tests including those described below.

In addition, a compound of formula I (or salt or  
15 prodrug, etc.) may exhibit polymorphism or may form a solvate with water or an organic solvent. The present invention also encompasses any such polymorphic form, any solvate or any mixture thereof.

A prodrug of a compound of formula I may be one formed  
20 in a conventional manner with a functional group of the compound, such as with an amino, hydroxy or carboxy group.


A compound of formula I may be prepared by processes which include processes known in the chemical art for the production of structurally analogous compounds or by a novel  
25 process described herein. A process for the preparation of a compound of formula I (or a pharmaceutically acceptable salt thereof) and novel intermediates for the manufacture of a compound of formula I as defined above provide further features of the invention and are illustrated by the  
30 following procedures in which the meanings of the generic radicals are as defined above, unless otherwise specified. It will be recognized that it may be preferred or necessary to prepare a compound of formula I in which a functional group is protected using a conventional protecting group,

- 9 -

then to remove the protecting group to provide the compound of formula I.

Thus, there is provided a process for preparing a compound of formula I (or a pharmaceutically acceptable salt thereof) as provided in any of the above descriptions which is selected from any of those described in the examples, including the following.

(A) Acylating an amine of formula II,




10

using a corresponding acid of formula  $\text{HO}-\text{CO}-\text{Q}^2$ , or an activated derivative thereof. Typical activated derivatives include the acid halides, activated esters, including 4-nitrophenyl esters and those derived from coupling reagents. Typical procedures include one similar to that described at example 1-E for the preparation of a protected intermediate.

(B) For a compound of formula I in which  $\text{Q}^2$  is  $\text{Q}^{2\text{B}}$ , acylating a pyrazine of formula  $\text{H}-\text{Q}^{2\text{B}}$  using an activated derivative of an acid of formula III,

20



particularly the corresponding acid chloride or 4-nitrophenyl ester.

(C) For a compound of formula I in which R is  $-\text{CHRYR}^Z$  or  $-\text{CHR}^W\text{R}^X$ , alkylating the amino nitrogen of a corresponding compound of formula I in which R is hydrogen using an alkylating agent of formula  $\text{Y}-\text{CHRYR}^Z$  or  $\text{Y}-\text{CHR}^W\text{R}^X$  or, preferably, reductively alkylating the amine using a

25

- 10 -

compound of formula  $RY-CO-R^Z$  or  $R^W-CO-R^X$ . The direct alkylation may be completed in a polar solvent in the presence of a base. The reductive alkylation conveniently is carried out, for example as described in the examples, using sodium cyanoborohydride in methanol/acetic acid or using sodium triacetoxymorohydride in an inert solvent such as 1,2-dichloroethane along with glacial acetic acid and an excess of the carbonyl compound.

Whereafter, for any of the above procedures, when a functional group is protected using a protecting group, removing the protecting group.

Whereafter, for any of the above procedures, when a pharmaceutically acceptable salt of a compound of formula I is required, it is obtained by reacting the basic form of a basic compound of formula I with an acid affording a physiologically acceptable counterion or the acidic form of an acidic compound of formula I with a base affording a physiologically acceptable counterion or by any other conventional procedure.

A novel intermediate or starting material compound provides a further aspect of the invention. The various starting material may be made by processes which include processes known in the chemical art for the production of structurally analogous compounds or by a novel process described herein or one analogous thereto.

As mentioned above, a compound corresponding to a compound of formula I but in which a functional group is protected may serve as an intermediate for a compound of formula I. Accordingly, such a protected intermediate for a novel compound of formula I provides a further aspect of the invention. Thus, as one particular aspect of the invention, there is provided a compound corresponding to a novel compound of formula I as defined above in which there is a hydroxy, but in which the corresponding substituent is -OPP

- 11 -

in place of hydroxy, wherein PP is a phenol protecting group other than methyl. Phenol protecting groups are well known in the art, for example as described in T.W. Greene and P.G.M. Wuts, "Protecting Groups in Organic Synthesis" (1991). Further, PP may denote a functionalized resin, for example as disclosed in H.V. Meyers, et al., Molecular Diversity, (1995), 1, 13-20.

As mentioned above, the invention includes a pharmaceutically acceptable salt of the factor Xa inhibiting compound defined by the above formula I. A basic compound of this invention possesses one or more functional groups sufficiently basic to react with any of a number of inorganic and organic acids affording a physiologically acceptable counterion to form a pharmaceutically acceptable salt. Acids commonly employed to form pharmaceutically acceptable acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromobenzenesulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycollate, tartrate, methanesulfonate,

- 12 -

propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like. Preferred pharmaceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid, hydrobromic acid and sulfuric acid.

If not commercially available, a necessary starting material for the preparation of a compound of formula I may be prepared by a procedure which is selected from standard techniques of organic chemistry, including aromatic and heteroaromatic substitution and transformation, from techniques which are analogous to the syntheses of known, structurally similar compounds, and techniques which are analogous to the above described procedures or procedures described in the Examples. It will be clear to one skilled in the art that a variety of sequences is available for the preparation of the starting materials. Starting materials which are novel provide another aspect of the invention.

Selective methods of substitution, protection and deprotection are well known in the art for preparation of a compound such as one of formula II.

Generally, a basic compound of the invention is isolated best in the form of an acid addition salt. A salt of a compound of formula I formed with an acid such as one of those mentioned above is useful as a pharmaceutically acceptable salt for administration of the antithrombotic agent and for preparation of a formulation of the agent. Other acid addition salts may be prepared and used in the isolation and purification of the compounds.

As noted above, the optically active isomers and diastereomers of the compounds of formula I are also considered part of this invention. Such optically active isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. This resolution can be

- 13 -

carried out by derivatization with a chiral reagent followed by chromatography or by repeated crystallization. Removal of the chiral auxiliary by standard methods affords substantially optically pure isomers of the compounds of the present invention or their precursors. Further details  
5 regarding resolutions can be obtained in Jacques, et al., Enantiomers, Racemates, and Resolutions, John Wiley & Sons, 1981.

The compounds of the invention are believed to  
10 selectively inhibit factor Xa over other proteinases and nonenzyme proteins involved in blood coagulation without appreciable interference with the body's natural clot lysing ability (the compounds have a low inhibitory effect on fibrinolysis). Further, such selectivity is believed to  
15 permit use with thrombolytic agents without substantial interference with thrombolysis and fibrinolysis.

The invention in one of its aspects provides a method of inhibiting factor Xa in mammals comprising administering to a mammal in need of treatment an effective (factor Xa  
20 inhibiting) dose of a compound of formula I.

In another of its aspects, the invention provides a method of treating a thromboembolic disorder comprising administering to a mammal in need of treatment an effective (thromboembolic disorder therapeutic and/or prophylactic  
25 amount) dose of a compound of formula I.

The invention in another of its aspects provides a method of inhibiting coagulation in a mammal comprising administering to a mammal in need of treatment an effective (coagulation inhibiting) dose of a compound of formula I.

30 The factor Xa inhibition, coagulation inhibition and thromboembolic disorder treatment contemplated by the present method includes both medical therapeutic and/or prophylactic treatment as appropriate.

- 14 -

In a further embodiment, the invention relates to treatment, in a human or animal, of a condition where inhibition of factor Xa is required. The compounds of the invention are expected to be useful in mammals, including  
5 man, in treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues. Disorders in which the compounds have a potential utility are in treatment or prophylaxis of thrombosis and hypercoagulability in blood and tissues. Disorders in which the compounds have a  
10 potential utility, in treatment and/or prophylaxis, include venous thrombosis and pulmonary embolism, arterial thrombosis, such as in myocardial ischemia, myocardial infarction, unstable angina, thrombosis-based stroke and peripheral arterial thrombosis. Further, the compounds have  
15 expected utility in the treatment or prophylaxis of atherosclerotic disorders (diseases) such as coronary arterial disease, cerebral arterial disease and peripheral arterial disease. Further, the compounds are expected to be useful together with thrombolytics in myocardial infarction.  
20 Further, the compounds have expected utility in prophylaxis for reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary bypass operations. Further, the compounds have expected utility in prevention of rethrombosis after microsurgery. Further, the  
25 compounds are expected to be useful in anticoagulant treatment in connection with artificial organs, including joint replacement, and cardiac valves. Further, the compounds have expected utility in anticoagulant treatment in hemodialysis and disseminated intravascular coagulation.  
30 A further expected utility is in rinsing of catheters and mechanical devices used in patients *in vivo*, and as an anticoagulant for preservation of blood, plasma and other blood products *in vitro*. Still further, the compounds have expected utility in other diseases where blood coagulation



- 15 -

could be a fundamental contributing process or a source of secondary pathology, such as cancer, including metastasis, inflammatory diseases, including arthritis, and diabetes. The anti-coagulant compound is administered orally or  
5 parenterally, e.g. by intravenous infusion (iv), intramuscular injection (im) or subcutaneously (sc).

The specific dose of a compound administered according to this invention to obtain therapeutic and/or prophylactic effects will, of course, be determined by the particular  
10 circumstances surrounding the case, including, for example, the compound administered, the rate of administration, the route of administration, and the condition being treated.

A typical daily dose for each of the above utilities is between about 0.01 mg/kg and about 1000 mg/kg. The dose  
15 regimen may vary e.g. for prophylactic use a single daily dose may be administered or multiple doses such as 3 or 5 times daily may be appropriate. In critical care situations a compound of the invention is administered by iv infusion at a rate between about 0.01 mg/kg/h and about 20 mg/kg/h  
20 and preferably between about 0.1 mg/kg/h and about 5 mg/kg/h.

The method of this invention also is practiced in conjunction with a clot lysing agent e.g. tissue plasminogen activator (t-PA), modified t-PA, streptokinase or urokinase.  
25 In cases when clot formation has occurred and an artery or vein is blocked, either partially or totally, a clot lysing agent is usually employed. A compound of the invention can be administered prior to or along with the lysing agent or subsequent to its use, and preferably further is  
30 administered along with aspirin to prevent the reoccurrence of clot formation.

The method of this invention is also practiced in conjunction with a platelet glycoprotein receptor (IIb/IIIa) antagonist, that inhibits platelet aggregation. A compound

- 16 -

of the invention can be administered prior to or along with the IIb/IIIa antagonist or subsequent to its use to prevent the occurrence or reoccurrence of clot formation.

The method of this invention is also practiced in conjunction with aspirin. A compound of the invention can be administered prior to or along with aspirin or subsequent to its use to prevent the occurrence or reoccurrence of clot formation. As stated above, preferably a compound of the present invention is administered in conjunction with a clot lysing agent and aspirin.

This invention also provides a pharmaceutical composition for use in the above described therapeutic method. A pharmaceutical composition of the invention comprises an effective factor Xa inhibiting amount of a compound of formula I in association with a pharmaceutically acceptable carrier, excipient or diluent.

The active ingredient in such formulations comprises from 0.1 percent to 99.9 percent by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

For oral administration the antithrombotic compound is formulated in gelatin capsules or tablets which may contain excipients such as binders, lubricants, disintegration agents and the like. For parenteral administration the antithrombotic is formulated in a pharmaceutically acceptable diluent e.g. physiological saline (0.9 percent), 5 percent dextrose, Ringer's solution and the like.

The compound of the present invention can be formulated in unit dosage formulations comprising a dose between about 0.1 mg and about 1000 mg. Preferably the compound is in the form of a pharmaceutically acceptable salt such as for example the sulfate salt, acetate salt or a phosphate salt.

- 17 -

An example of a unit dosage formulation comprises 5 mg of a compound of the present invention as a pharmaceutically acceptable salt in a 10 mL sterile glass ampoule. Another example of a unit dosage formulation comprises about 10 mg  
5 of a compound of the present invention as a pharmaceutically acceptable salt in 20 mL of isotonic saline contained in a sterile ampoule.

The compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous,  
10 intravenous, intramuscular, and intranasal. The compounds of the present invention are preferably formulated prior to administration.

The present pharmaceutical compositions are prepared by known procedures using well known and readily available  
15 ingredients. The compositions of this invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. In making the compositions of the present invention, the active  
20 ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a  
25 vehicle, excipient or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, (as a solid or in a liquid medium), soft and hard gelatin capsules,  
30 suppositories, sterile injectable solutions, sterile packaged powders, and the like.

The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way. "Active ingredient," of course, means

- 18 -

a compound according to formula I or a pharmaceutically acceptable salt or solvate thereof.

- Formulation 1: Hard gelatin capsules are prepared  
5 using the following ingredients:

	Quantity (mg/capsule)
Active ingredient	250
Starch, dried	200
Magnesium stearate	<u>10</u>
Total	460 mg

- Formulation 2: A tablet is prepared using the  
ingredients below:

	Quantity (mg/tablet)
Active ingredient	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	<u>5</u>
Total	665 mg

- 10 The components are blended and compressed to form tablets  
each weighing 665 mg.

- Formulation 3: An aerosol solution is prepared  
containing the following components:

	Weight
Active ingredient	0.25
Ethanol	29.75
Propellant 22 (Chlorodifluoromethane)	<u>70.00</u>
Total	100.00

15

- The active compound is mixed with ethanol and the mixture

- 19 -

added to a portion of the propellant 22, cooled to -30 °C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then  
5 fitted to the container.

Formulation 4: Tablets, each containing 60 mg of active ingredient, are made as follows:

Active ingredient	60 mg
Starch	45 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	<u>1 mg</u>
Total	150 mg

10

The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed  
15 through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50 °C and passed through a No. 18 mesh U.S. Sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing,  
20 are compressed on a tablet machine to yield tablets each weighing 150 mg.

- 20 -

Formulation 5: Capsules, each containing 80 mg of active ingredient, are made as follows:

Active ingredient	80 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	<u>2 mg</u>
Total	200 mg

- 5 The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

- 10 Formulation 6: Suppositories, each containing 225 mg of active ingredient, are made as follows:

Active ingredient	225 mg
Saturated fatty acid glycerides	<u>2,000 mg</u>
Total	2,225 mg

- 15 The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

- 20 Formulation 7: Suspensions, each containing 50 mg of active ingredient per 5 mL dose, are made as follows:

Active ingredient	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mL
Benzoic acid solution	0.10 mL

- 21 -

Flavor	q.v.
Color	q.v.
Purified water to total	5 mL

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, 5 flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Formulation 8: An intravenous formulation may be 10 prepared as follows:

Active ingredient	100 mg
Isotonic saline	1,000 mL

The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 mL 15 per minute.

The ability of a compound of the present invention to be an effective and orally active factor Xa inhibitor may be evaluated in one or more of the following assays or in other standard assays known to those in the art.

20 The inhibition by a compound of the inhibition of a serine protease of the human blood coagulation system or of the fibrinolytic system, as well as of trypsin, is determined in vitro for the particular enzyme by measuring its inhibitor binding affinity in an assay in which the 25 enzyme hydrolyzes a particular chromogenic substrate, for example as described in Smith, G.F.; Gifford-Moore, D.; Craft, T.J.; Chirgadze, N.; Ruterbories, K.J.; Lindstrom, T.D.; Satterwhite, J.H. Efegacran: A New Cardiovascular Anticoagulant. *New Anticoagulants for the Cardiovascular*

- 22 -

Patient; Pifarre, R., Ed.; Hanley & Belfus, Inc.:  
Philadelphia, 1997; pp. 265-300. The inhibitor binding  
affinity is measured as apparent association constant  $K_{ass}$   
which is the hypothetical equilibrium constant for the  
5 reaction between enzyme and the test inhibitor compound (I).



$$K_{ass} = \frac{[\text{Enzyme-I}]}{[(\text{Enzyme}) \times (\text{I})]}$$

Conveniently, enzyme inhibition kinetics are performed  
10 in 96-well polystyrene plates and reaction rates are  
determined from the rate of hydrolysis of appropriate  
p-nitroanilide substrates at 405 nm using a Thermomax plate  
reader from Molecular Devices (San Francisco, CA). The same  
protocol is followed for all enzymes studied: 50  $\mu\text{L}$  buffer  
15 (0.03 M Tris, 0.15 M NaCl pH 7) in each well, followed by  
25  $\mu\text{L}$  of inhibitor solution (in 100% methanol, or in 50% v:v  
aqueous methanol) and 25  $\mu\text{L}$  enzyme solution; within two  
minutes, 150  $\mu\text{L}$  aqueous solution of chromogenic substrate  
(0.25 mg/mL) is added to start the enzymatic reaction. The  
20 rates of chromogenic substrate hydrolysis reactions provide  
a linear relationship with the enzymes studied such that  
free enzyme can be quantitated in reaction mixtures. Data  
is analyzed directly as rates by the Softmax program to  
produce [free enzyme] calculations for tight-binding  $K_{ass}$   
25 determinations. For apparent  $K_{ass}$  determinations, 1.34 nM  
human factor Xa is used to hydrolyze 0.18 mM BzIle-Glu-Gly-  
Arg-pNA; 5.9 nM human thrombin or 1.4 nM bovine trypsin is  
used to hydrolyze 0.2 mM BzPhe-Val-Arg-pNA; 3.4 nM human  
plasmin is used with 0.5 mM HD-Val-Leu-Lys-pNA; 1.2 nM human  
30 nt-PA is used with 0.81 mM HD-Ile-Pro-Arg-pNA; and 0.37 nM  
urokinase is used with 0.30 mM pyro-gfsGlu-Gly-Arg-pNA.



- 23 -

Kass is calculated for a range of concentrations of test compounds and the mean value reported in units of liter per mole. In general, a factor Xa inhibiting compound of formula I of the instant invention, as exemplified herein, exhibits a Kass of 0.1 to  $0.5 \times 10^6$  L/mole or much greater.

The factor Xa inhibitor preferably should spare fibrinolysis induced by urokinase, tissue plasminogen activator (t-PA) and streptokinase. This would be important to the therapeutic use of such an agent as an adjunct to streptokinase, tp-PA or urokinase thrombolytic therapy and to the use of such an agent as an endogenous fibrinolysis-sparing (with respect to t-PA and urokinase) antithrombotic agent. In addition to the lack of interference with the amidase activity of the fibrinolytic proteases, such fibrinolytic system sparing can be studied by the use of human plasma clots and their lysis by the respective fibrinolytic plasminogen activators.

#### Materials

Dog plasma is obtained from conscious mixed-breed hounds (either sex Butler Farms, Clyde, New York, U.S.A.) by venipuncture into 3.8 percent citrate. Fibrinogen is prepared from fresh dog plasma and human fibrinogen is prepared from in-date ACD human blood at the fraction I-2 according to previous procedures and specification. Smith, Biochem. J., 185, 1-11 (1980; and Smith, et al., Biochemistry, 11, 2958-2967, (1972). Human fibrinogen (98 percent pure/plasmin free) is from American Diagnostica, Greenwich, Connecticut. Radiolabeling of fibrinogen I-2 preparations is performed as previously reported. Smith, et al., Biochemistry, 11, 2958-2967, (1972). Urokinase is purchased from Leo Pharmaceuticals, Denmark, as 2200 Ploug units/vial. Streptokinase is purchased from Hoechst-Roussel Pharmaceuticals, Somerville, New Jersey.

- 24 -

Methods - Effects on Lysis of Human Plasma Clots by t-PA

Human plasma clots are formed in micro test tubes by adding 50  $\mu$ L thrombin (73 NIH unit/mL) to 100  $\mu$ L human plasma which  
5 contains 0.0229  $\mu$ Ci 125-iodine labeled fibrinogen. Clot lysis is studied by overlaying the clots with 50  $\mu$ L of urokinase or streptokinase (50, 100, or 1000 unit/mL) and incubating for 20 hours at room temperature. After incubation the tubes are centrifuged in a Beckman Microfuge.  
10 25  $\mu$ L of supernate is added into 1.0 mL volume of 0.03 M tris/0.15 M NaCl buffer for gamma counting. Counting controls 100 percent lysis are obtained by omitting thrombin (and substituting buffer). The factor Xa inhibitors are evaluated for possible interference with fibrinolysis by  
15 including the compounds in the overlay solutions at 1, 5, and 10  $\mu$ g/mL concentrations. Rough approximations of IC<sub>50</sub> values are estimated by linear extrapolations from data points to a value which would represent 50 percent of lysis for that particular concentration of fibrinolytic agent.

20

Anticoagulant ActivityMaterials

Dog plasma and rat plasma are obtained from conscious mixed-breed hounds (either sex, Butler Farms, Clyde, New York,  
25 U.S.A.) or from anesthetized male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc., Indianapolis, Indiana, U.S.A.) by venipuncture into 3.8 percent citrate. Fibrinogen is prepared from in-date ACD human blood as the fraction I-2 according to previous procedures and specifications. Smith,  
30 Biochem. J., 185, i-11 (1980); and Smith, et al., Biochemistry, 11, 2958-2967 (1972). Human fibrinogen is also purchased as 98 percent pure/plasmin free from American Diagnostica, Greenwich, Connecticut. Coagulation reagents Actin, Thromboplastin, Innovin and Human plasma are from

- 25 -

Baxter Healthcare Corp., Dade Division, Miami, Florida.  
Bovine thrombin from Parke-Davis (Detroit, Michigan) is used  
for coagulation assays in plasma.

## 5 Methods

### Anticoagulation Determinations

Coagulation assay procedures are as previously described.  
Smith, et al., Thrombosis Research, 50, 163-174 (1988). A  
CoAScreener coagulation instrument (American LABor, Inc.) is  
10 used for all coagulation assay measurements. The  
prothrombin time (PT) is measured by adding 0.05 mL saline  
and 0.05 mL Thromboplastin-C reagent or recombinant human  
tissue factor reagent (Innovin) to 0.05 mL test plasma. The  
activated partial thromboplastin time (APTT) is measured by  
15 incubation of 0.05 mL test plasma with 0.05 mL Actin reagent  
for 120 seconds followed by 0.05 mL  $\text{CaCl}_2$  (0.02 M). The  
thrombin time (TT) is measured by adding 0.05 mL saline and  
0.05 mL thrombin (10 NIH units/mL) to 0.05 mL test plasma.  
The compounds of formula I are added to human or animal  
20 plasma over a wide range of concentrations to determine  
prolongation effects on the APTT, PT, and TT assays. Linear  
extrapolations are performed to estimate the concentrations  
required to double the clotting time for each assay.

## 25 Animals

Male Sprague Dawley rats (350-425 gm, Harlan Sprague Dawley  
Inc., Indianapolis, IN) are anesthetized with xylazine (20  
mg/kg, s.c.) and ketamine (120 mg/kg, s.c.) and maintained  
on a heated water blanket (37 °C). The jugular vein(s) is  
30 cannulated to allow for infusions.

### Arterio-Venous shunt model

The left jugular vein and right carotid artery are  
cannulated with 20 cm lengths of polyethylene PE 60 tubing.

- 26 -

A 6 cm center section of larger tubing (PE 190) with a cotton thread (5 cm) in the lumen, is friction fitted between the longer sections to complete the arterio-venous shunt circuit. Blood is circulated through the shunt for 15 min before the thread is carefully removed and weighed. The weight of a wet thread is subtracted from the total weight of the thread and thrombus (see J.R. Smith, Br J Pharmacol, 77:29, 1982).

10 FeCl<sub>3</sub> model of arterial injury

The carotid arteries are isolated via a midline ventral cervical incision. A thermocouple is placed under each artery and vessel temperature is recorded continuously on a strip chart recorder. A cuff of tubing (0.058 ID x 0.077 OD x 4 mm, Baxter Med. Grade Silicone), cut longitudinally, is placed around each carotid directly above the thermocouple. FeCl<sub>3</sub> hexahydrate is dissolved in water and the concentration (20 percent) is expressed in terms of the actual weight of FeCl<sub>3</sub> only. To injure the artery and induce thrombosis, 2.85 µL is pipetted into the cuff to bathe the artery above the thermocouple probe. Arterial occlusion is indicated by a rapid drop in temperature. The time to occlusion is reported in minutes and represents the elapsed time between application of FeCl<sub>3</sub> and the rapid drop in vessel temperature (see K.D. Kurz, Thromb. Res., 60:269, 1990).

Coagulation parameters

Plasma thrombin time (TT) and activated partial thromboplastin time (APTT) are measured with a fibrometer. Blood is sampled from a jugular catheter and collected in syringe containing sodium citrate (3.8 percent, 1 part to 9 parts blood). To measure TT, rat plasma (0.1 mL) is mixed with saline (0.1 mL) and bovine thrombin (0.1 mL, 30 U/mL in

- 27 -

TRIS buffer; Parke Davis) at 37 °C. For APTT, plasma (0.1 mL) and APTT solution (0.1 mL, Organon Teknika) are incubated for 5 minutes (37 °C) and CaCl<sub>2</sub> (0.1 mL, 0.025 M) is added to start coagulation. Assays are done in duplicate and averaged.

#### Index of Bioavailability

Bioavailability studies may be conducted as follows. Compounds are administered as aqueous solutions to male Fisher rats, intravenously (iv) at 5 mg/kg via tail vein injection and orally (po) to fasted animals at 20 mg/kg by gavage. Serial blood samples are obtained at 5, 30, 120, and 240 minutes postdose following intravenous administration and at 1, 2, 4, and 6 hours after oral dosing. Plasma is analyzed for drug concentration using an HPLC procedure involving C8 Bond Elute (Varion) cartridges for sample preparation and a methanol/30 mM ammonium acetate buffer (pH 4) gradient optimized for each compound. % Oral bioavailability is calculated by the following equation:

$$\% \text{ Oral bioavailability} = \frac{\text{AUC po}}{\text{AUC iv}} \times \frac{\text{Dose iv}}{\text{Dose po}} \times 100$$

where AUC is area under the curve calculated from the plasma level of compound over the time course of the experiment following oral (AUC po) and intravenous (AUC iv) dosing.

#### Compounds

Compound solutions are prepared fresh daily in normal saline and are injected as a bolus or are infused starting 15 minutes before and continuing throughout the experimental perturbation which is 15 minutes in the arteriovenous shunt model and 60 minutes in the FeCl<sub>3</sub> model of arterial injury and in the spontaneous thrombolysis model. Bolus injection

- 28 -

volume is 1 mL/kg for i.v., and 5 mL/kg for p.o., and infusion volume is 3 mL/hr.

#### Statistics

- 5 Results are expressed as means  $\pm$  SEM. One-way analysis of variance is used to detect statistically significant differences and then Dunnett's test is applied to determine which means are different. Significance level for rejection of the null hypothesis of equal means is  $P < 0.05$ .

10

#### Animals

- Male dogs (Beagles; 18 months - 2 years; 12-13 kg, Marshall Farms, North Rose, New York 14516) are fasted overnight and fed Purina certified Prescription Diet (Purina Mills, St. Louis, Missouri) 240 minutes after dosing. Water is available *ad libitum*. The room temperature is maintained between 66-74 °F; 45-50 percent relative humidity; and lighted from 0600-1800 hours.

#### 20 Pharmacokinetic model.

- Test compound is formulated immediately prior to dosing by dissolving in sterile 0.9 percent saline to a 5 mg/mL preparation. Dogs are given a single 2 mg/kg dose of test compound by oral gavage. Blood samples (4.5 mL) are taken from the cephalic vein at 0.25, 0.5, 0.75, 1, 2, 3, 4 and 6 hours after dosing. Samples are collected in citrated Vacutainer tubes and kept on ice prior to reduction to plasma by centrifugation. Plasma samples are analyzed by HPLC MS. Plasma concentration of test compound is recorded and used to calculate the pharmacokinetic parameters: elimination rate constant,  $K_e$ ; total clearance,  $Cl_t$ ; volume of distribution,  $V_D$ ; time of maximum plasma test compound concentration,  $T_{max}$ ; maximum concentration of test compound

- 29 -

of T<sub>max</sub>, C<sub>max</sub>; plasma half-life, t<sub>0.5</sub>; and area under the curve, A.U.C.; fraction of test compound absorbed, F.

#### Canine Model of Coronary Artery Thrombosis

- 5 Surgical preparation and instrumentation of the dogs are as described in Jackson, et al., Circulation, 82, 930-940 (1990). Mixed-breed hounds (aged 6-7 months, either sex, Butler Farms, Clyde, New York, U.S.A.) are anesthetized with sodium pentobarbital (30 mg/kg intravenously, i.v.),
- 10 intubated, and ventilated with room air. Tidal volume and respiratory rates are adjusted to maintain blood PO<sub>2</sub>, PCO<sub>2</sub>, and pH within normal limits. Subdermal needle electrodes are inserted for the recording of a lead II ECG.
- 15 The left jugular vein and common carotid artery are isolated through a left mediolateral neck incision. Arterial blood pressure (ABP) is measured continuously with a precalibrated Millar transducer (model (MPC-500, Millar Instruments, Houston, TX, U.S.A.) inserted into the carotid artery. The
- 20 jugular vein is cannulated for blood sampling during the experiment. In addition, the femoral veins of both hindlegs are cannulated for administration of test compound.

- A left thoracotomy is performed at the fifth intercostal
- 25 space, and the heart is suspended in a pericardial cradle. A 1- to 2-cm segment of the left circumflex coronary artery (LCX) is isolated proximal to the first major diagonal ventricular branch. A 26-gauge needle-tipped wire anodal electrode (Teflon-coated, 30-gauge silverplated copper wire)
- 30 3-4 mm long is inserted into the LCX and placed in contact with the intimal surface of the artery (confirmed at the end of the experiment). The stimulating circuit is completed by placing the cathode in a subcutaneous (s.c.) site. An adjustable plastic occluder is placed around the LCX, over

- 30 -

the region of the electrode. A precalibrated electromagnetic flow probe (Carolina Medical Electronics, King, NC, U.S.A.) is placed around the LCX proximal to the anode for measurement of coronary blood flow (CBF). The occluder is adjusted to produce a 40-50 percent inhibition of the hyperemic blood flow response observed after 10-s mechanical occlusion of the LCX. All hemodynamic and ECG measurements are recorded and analyzed with a data acquisition system (model M3000, Modular Instruments, Malvern, PA. U.S.A.).

#### Thrombus Formation and Compound Administration Regimens

Electrolytic injury of the intima of the LCX is produced by applying 100- $\mu$ A direct current (DC) to the anode. The current is maintained for 60 min and then discontinued whether the vessel has occluded or not. Thrombus formation proceeds spontaneously until the LCX is totally occluded (determined as zero CBF and an increase in the S-T segment). Compound administration is started after the occluding thrombus is allowed to age for 1 hour. A 2-hour infusion of the compounds of the present invention at doses of 0.5 and 1 mg/kg/hour is begun simultaneously with an infusion of thrombolytic agent (e.g. tissue plasminogen activator, streptokinase, APSAC). Reperfusion is followed for 3 hour after administration of test compound. Reocclusion of coronary arteries after successful thrombolysis is defined as zero CBF which persisted for at least 30 minutes.

#### Hematology and template bleeding time determinations

Whole blood cell counts, hemoglobin, and hematocrit values are determined on a 40- $\mu$ L sample of citrated (3.8 percent) blood (1 part citrate:9 parts blood) with a hematology analyzer (Cell-Dyn 900, Sequoia-Turner. Mount View, CA, U.S.A.). Gingival template bleeding times are determined



- 31 -

with a Simplate II bleeding time device (Organon Teknika Durham, N.C., U.S.A.). The device is used to make 2 horizontal incisions in the gingiva of either the upper or lower left jaw of the dog. Each incision is 3 mm wide x 2 mm deep. The incisions are made, and a stopwatch is used to determine how long bleeding occurs. A cotton swab is used to soak up the blood as it oozes from the incision. Template bleeding time is the time from incision to stoppage of bleeding. Bleeding times are taken just before administration of test compound (0 min), 60 min into infusion, at conclusion of administration of the test compound (120 min), and at the end of the experiment.

All data are analyzed by one-way analysis of variance (ANOVA) followed by Student-Neuman-Kuels post hoc *t* test to determine the level of significance. Repeated-measures ANOVA are used to determine significant differences between time points during the experiments. Values are determined to be statistically different at least at the level of  $p < 0.05$ . All values are mean  $\pm$  SEM. All studies are conducted in accordance with the guiding principles of the American Physiological Society. Further details regarding the procedures are described in Jackson, et al., J. Cardiovasc. Pharmacol., (1993), 21, 587-599.

25

The following Examples are provided to further describe the invention and are not to be construed as limitations thereof.

The abbreviations, symbols and terms used in the examples have the following meanings.

Ac = acetyl

Anal. = elemental analysis

aq = aqueous

Boc = t-butyloxycarbonyl

- 32 -

Calcd = calculated  
DMF = dimethylformamide  
DMSO = dimethylsulfoxide  
FTIR = Fourier transform IR  
5 HPLC = High Performance Liquid Chromatography  
IR = Infrared Spectrum  
MS-FD or MS (FD) = field desorption mass spectrum  
MS-IS (or IS-MS) = ion spray mass spectrum  
NMR = Nuclear Magnetic Resonance  
10 RPHPLC = Reversed Phase High Performance Liquid  
Chromatography  
RT (or  $R_t$ ) = retention time  
satd = saturated  
SCX = strong cation exchange (resin)  
15 TFA = trifluoroacetic acid  
THF = tetrahydrofuran

Unless otherwise stated, pH adjustments and work up are  
with aqueous acid or base solutions.  $^1\text{H}$ -NMR indicates a  
20 satisfactory NMR spectrum was obtained for the compound  
described. IR (or FTIR) indicates a satisfactory infra red  
spectrum was obtained for the compound described.


Analytical HPLC method was a linear gradient of 90/10 to  
25 50/50 (0.1% TFA in water/0.1% TFA in acetonitrile) over 40  
minutes with a flow rate of 1 mL/min.

- 33 -

## Examples 1-13

Examples 1-13 are of the following general formula in which the value of R is defined for each example.

5



## Example 1

Preparation of 1-(Piperidin-4-yl-carbonyl)-4-(6-chloro-naphthalen-2-ylsulfonyl)piperazine Trifluoroacetate (R=H)

## A. 6-Chloro-2-naphthalenesulfonic acid

6-Amino-2-naphthalenesulfonic acid (88.0 g, 0.4 mol) was suspended in 5 N HCl (200 mL) and water (150 mL) and cooled to 3 °C. A solution of sodium nitrite (27.0 g, 0.4 mol) in water (50 mL) was added dropwise over two hours. After one additional hour, the mixture was poured in several portions into a stirred suspension of copper(I) chloride (39.6 g, 60.6 mmol) in 5 N HCl (200 mL). Considerable foaming occurred during this addition. After standing overnight at room temperature, the mixture was concentrated on a rotary evaporator to a brown solid that was then dried in a vacuum oven overnight at 100 °C to provide the acid (111.9 g).

## B. 6-Chloro-2-naphthalenesulfonyl chloride

To a stirring solution of naphthalene sulfonic acid (12 g) in DMF (40 mL) at 0 °C was added dropwise thionyl chloride (9 mL). After 3 h the mixture was poured over ice then extracted twice with methylene chloride. The combined



- 34 -

organic extracts were washed with water and brine, and dried over sodium sulfate, then adsorbed onto silica and filtered through a pad of silica, eluting with 50% ethyl acetate: 50% hexanes. The solvents were then evaporated in vacuo to give  
5 2.8 g of oil that crystallized on standing. The product was chromatographed on a (Biotage) silica column, eluting with ethyl acetate:hexanes (1:9), to yield 1.6 g pure product.  
 $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  (dd, 1H, 7.64,  $J=1,12$ ), (m, 4H, 7.9-8.2), (s, 1H, 8.6);  
10 MS (FD) 259.9 M+.

C. 1-Boc-4-(6-chloronaphthalen-2-ylsulfonyl)piperazine  
To a stirring solution of N-Boc-piperazine (400 mg, 2.1 mmol) and triethylamine (1 mL, 7 mmol) in methylene  
15 chloride (5 mL) was added 6-chloro-2-naphthalenesulfonyl chloride (500 mg, 1.9 mmol). After 2 h the solution was washed with water, dried over sodium sulfate and evaporated. The residue was chromatographed on a (Biotage) silica column eluting with ethyl acetate:hexanes (2:8) to give 300 mg  
20 (38%).  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  (s, 9H, 1.4), (m, 4H, 3.07), (m, 4H, 3.55), (dd, 1H, 7.55,  $J=1,12$ ), (dd, 1H, 7.75,  $J=1,12$ ), (m, 4H, 7.9), (s, 1H, 8.3),  
MS (FD) 410.1 M+;  
IR (chloroform) carbonyl  $1691\text{ cm}^{-1}$ .  
25 Anal.

Calcd: C, 55.54; H, 5.64; N, 6.82; Cl, 8.63;

Found: C, 55.71; H, 5.76; N, 6.85; Cl, 8.76.

D. 1-(6-chloronaphthalen-2-ylsulfonyl)piperazine  
30 To a stirring suspension of 1-Boc-4-(6-chloro-naphthalen-2-ylsulfonyl)piperazine (2.8g, 6.8 mmol) in dioxane (50 mL) was added 4 M HCl in dioxane (5 mL, 40 mmol). After stirring overnight at room temperature, the solvent was evaporated in vacuo, and the residue was

- 35 -

dissolved in water. The aqueous phase was and made basic with 5 N NaOH and extracted twice with ethyl acetate. The combined extracts were washed with water and brine, then dried over sodium sulfate and evaporated to 2.1 g (100%) solid.

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ ):  $\delta$  (m, 4H, 2.71), (m, 4H, 2.86), (dd, 1H, 7.7,  $J=1, 10$ ), (dd, 1H, 7.8,  $J=1, 10$ ), (d, 1H, 8.16,  $J=10$ ), (s, 1H, 8.22), (d, 1H, 8.25,  $J=10$ ), (s, 1H, 8.48);

MS 311.2 ( $M+1$ ).

Anal.

Calcd: C, 54.10; H, 4.86; N, 9.01; Cl, 11.41;

Found: C, 54.20; H, 4.88; N, 8.85; Cl, 11.66.

E. 1-(1-Boc-piperidin-4-ylcarbonyl)-4-(6-chloronaphthalen-2-ylsulfonyl)piperazine

To a stirring solution of N-Boc-isonipecotic acid (1.99 g, 8.7 mmol) in THF (50 mL) was added sodium ethoxide (0.592 g, 8.7 mmol). After 0.5 h, the solvent was removed in vacuo and the residue was suspended in dichloromethane (50 mL). To this mixture was added a couple drops of DMF, followed by oxalyl chloride (1.32 g, 10.4 mmol). After stirring for another hour, the solvent was removed in vacuo and the crude acid chloride resuspended in dichloromethane (25 mL). To this solution was added a solution of 1-(6-chloronaphthalen-2-ylsulfonyl)piperazine (1.8 g, 5.8 mmol) and pyridine (5 mL) in dichloromethane (25 mL). After stirring overnight, the solvent was removed in vacuo and the residue was partitioned between ethyl acetate and water. The layers were separated and the organic phase was washed twice with 1 M citric acid, once with brine, twice with satd aq  $\text{NaHCO}_3$  and twice again with brine, then dried with  $\text{MgSO}_4$ , filtered and concentrated in vacuo. The residue was then dissolved in a minimum amount of dichloromethane and chromatographed over silica gel, eluting with a step

- 36 -

gradient of 35% ethyl acetate in hexanes through 75% ethyl acetate in hexanes. The product containing fractions were combined and concentrated in vacuo to give 2.1 g (69%) of a white foam.

5  $^1\text{H}$ -NMRIS-MS m/z 522.2 (MH<sup>+</sup>)Anal. for  $\text{C}_{25}\text{H}_{32}\text{ClN}_3\text{O}_5\text{S}$ :

Calcd: C, 57.52; H, 6.18; N, 8.05;

Found: C, 57.65; H, 6.19; N, 7.76.

10

F. 1-(Piperidin-4-ylcarbonyl)-4-(6-chloronaphthalen-2-yl-sulfonyl)piperazine Trifluoroacetate

To a stirring solution of 1-(1-Boc-piperidin-4-yl-carbonyl)-4-(6-chloronaphthalen-2-ylsulfonyl)piperazine  
15 (2.2 g, 4.2 mmol) in dichloromethane (25 mL) was added anisole (2 mL) followed by TFA (25 mL). After 90 min, the solvents were removed in vacuo and the residue was dissolved in a few mL of dichloromethane and diluted with diethyl  
20 ether (200 mL). After stirring for 2 h, the suspension was sonicated and filtered and then the solid was washed with diethyl ether and dried in vacuo to give 2.25 g (99%) of a white solid.

 $^1\text{H}$ -NMRIS-MS m/z 422.2 (MH<sup>+</sup>)25 Anal. for  $\text{C}_{20}\text{H}_{24}\text{ClN}_3\text{O}_3\text{S} \cdot 1.1\text{TFA}$ :

Calcd: C, 48.71; H, 4.62; N, 7.68; F, 11.45;

Found: C, 48.32; H, 4.65; N, 7.56; F, 11.36.

- 37 -

For the preparation of the compounds in Examples 2-13 below, one of the following procedures was used.

Procedure A:

- 5           1-(Piperidin-4-ylcarbonyl)-4-(6-chloronaphthalen-2-ylsulfonyl)piperazine trifluoroacetate (50 mg, 0.93 mmol) was placed in a 10 mL round-bottom flask and dissolved in methanol (1 mL). Aldehyde (0.112 mmol) or ketone (1 mL) and glacial acetic acid (0.050 mL) were added to the solution.
- 10       Sodium cyanoborohydride (30 mg, 0.5 mmol) was then added. The reaction was stirred at room temperature until completion. The crude reaction mixture was then applied to a solid phase extraction (SPE) cartridge (strong cation exchange (SCX), 12 cc, 2 gram of packing material from
- 15       Varian Sample Preparation Products, Harbor City, CA) that was pre-washed once 95:5 methanol:AcOH (10 mL). The cartridge was then washed once with methanol (10 mL). Product was eluted with 1.0 M ammonia in methanol (10 mL). The resulting solution was concentrated in vacuo to afford
- 20       the alkylated product. If further purification was necessary, the product was dissolved in dichloromethane (3 mL) and applied to a silica gel cartridge (12 cc, 2 g of packing material from Varian Sample Preparation Products, Harbor City, CA). The cartridge was pre-washed with
- 25       dichloromethane (10 mL). Product was eluted with dichloromethane to 96:4 dichloromethane:methanol. The resulting solution was concentrated in vacuo to afford the alkylated product in 26-100% yield.

30       Procedure B:

          1-(Piperidin-4-ylcarbonyl)-4-(6-chloronaphthalen-2-ylsulfonyl)piperazine trifluoroacetate (50 mg, 0.093 mmol) was placed in a 10 mL round-bottom flask and suspended in 1,2-dichloroethane (1 mL). Benzaldehyde (1 mL) or



- 38 -

4-heptanone (1 mL) and glacial acetic acid (0.050 mL) was added to the solution. Sodium triacetoxymethylborohydride (100 mg, 0.5 mmol) was then added. The reaction was stirred at room temperature for 24 h. The crude reaction mixture was then applied to a solid phase extraction (SPE) cartridge (strong cation exchange (SCX), 12 cc, 2 gram of packing material from Varian Sample Preparation Products, Harbor City, CA) that was pre-washed once 95:5 methanol:AcOH (10 mL). The cartridge was then washed once with methanol (10 mL). Product was eluted with 1.0 M ammonia in methanol (10 mL). The resulting solution was concentrated in vacuo to afford the alkylated product. The product was dissolved in dichloromethane (3 mL) and applied to a silica gel cartridge (12 cc, 2 gram of packing material from Varian Sample Preparation Products, Harbor City, CA). The cartridge was pre-washed with dichloromethane (10 mL). Product was eluted with dichloromethane to 96:4 dichloromethane:methanol. The resulting solution was concentrated in vacuo to afford the alkylated product in 15-69% yield.

#### Example 2

R = cyclopentyl; Procedure A; 46 mg, 100% (95% pure);  
Analytical RPHPLC, RT = 22.68 min; IS-MS m/z 490.1 (MH+).

25

#### Example 3

R = cyclohexyl; Procedure A; 46 mg, 98% (96% pure);  
Analytical RPHPLC, RT = 24.55 min; IS-MS m/z 504.1 (MH+).

#### Example 4

R = benzyl; Procedure B; 33 mg, 69% (96% pure); Analytical  
RPHPLC, RT = 25.83 min; IS-MS m/z 512.1 (MH+).

30

#### Example 5

R = cycloheptyl; Procedure A; 46 mg, 96% (97% pure);  
Analytical RPHPLC, RT = 26.72 min; IS-MS m/z 518.2 (MH+).

- 39 -

**Example 6**

R = (2-pyridyl)methyl; Procedure A; 24 mg, 50% (88% pure);  
Analytical RPHPLC, RT = 21.04 min; IS-MS m/z 513.2 (MH+).

**Example 7**

- 5 R = (3-pyridyl)methyl; Procedure A; 14 mg, 29% (91% pure);  
Analytical RPHPLC, RT = 18.44 min; IS-MS m/z 513.1 (MH+).

**Example 8**

R = (4-pyridyl)methyl; Procedure A; 21 mg, 44% (79% pure);  
Analytical RPHPLC, RT = 17.40 min; IS-MS m/z 513.1 (MH+).

10

**Example 9**

R = 4-tetrahydropyranyl; Procedure A; 49 mg, 104% (93%  
pure); Analytical RPHPLC, RT = 20.14 min; IS-MS m/z 506.1  
(MH+).

**Example 10**

- 15 R = 4-thianyl; Procedure A; 45 mg, 92% (96% pure);  
Analytical RPHPLC, RT = 23.03 min; IS-MS m/z 522.1 (MH+).

**Example 11**

R = isopropyl; Procedure A; 43 mg, 100% (97% pure);  
Analytical RPHPLC, RT = 20.76 min; IS-MS m/z 464.1 (MH+).

20

**Example 12**

R = 3-pentyl; Procedure A; 12 mg, 26% (96% pure); Analytical  
RPHPLC, RT = 23.70 min; IS-MS m/z 492.1 (MH+).


**Example 13**

- 25 R = 4-heptyl; Procedure B; 7 mg, 15% (99% pure); Analytical  
RPHPLC, RT = 29.51 min; IS-MS m/z 520.1 (MH+).

- 40 -

What is claimed is:

1. A compound of formula I




(or a pharmaceutically acceptable salt thereof) wherein:

$\text{Q}^1$  is phenyl or 2-naphthalenyl either of which may bear one or more halo, trifluoromethyl, methoxy or methyl substituents;

$\text{L}^1$  is a direct bond, methylene, ethylene or ethen-1,2-diyl; and

$\text{Q}^2$  is  $\text{Q}^{2\text{A}}$ ,  $\text{Q}^{2\text{B}}$ , or  $\text{Q}^{2\text{C}}$  in which

$\text{Q}^{2\text{A}}$  (showing the CO to which it is attached) is



in which each of m and n independently is 0 or 1;

$\text{Q}^{2\text{B}}$  is 1-piperazinyl which bears at the 4-position the group R; and


$\text{Q}^{2\text{C}}$  is 3,4-didehydropiperidin-4-yl which bears at the 1-position the group R; and

R is t-butyl,  $-\text{CHR}^{\text{Y}}\text{R}^{\text{Z}}$ , or  $-\text{CHR}^{\text{W}}\text{R}^{\text{X}}$  wherein

each of  $\text{R}^{\text{W}}$  and  $\text{R}^{\text{X}}$  independently is hydrogen or

(1-3C)normal alkyl; or  $-\text{CHR}^{\text{W}}\text{R}^{\text{X}}$  is 2-indanyl or (showing the nitrogen to which it is attached) is

- 41 -



in which T is a single bond or methylene and U is methylene, ethylene, oxy,  $-S(O)_q-$  (wherein q is 0, 1 or 2) or imino (which may bear a methyl substituent), or T is  
 5 ethan-1,1-diyl and U is a single bond or methylene;

RY is hydrogen or methyl; and

R<sup>2</sup> is isopropyl, t-butyl, (3-6C)cycloalkyl, phenyl (which is unsubstituted or bears one or more substituents  
 10 independently selected from halo, methyl, methoxy and hydroxy), 4-quinolinyl or heteroaryl (which heteroaryl is a 5-membered aromatic ring which includes one to four heteroatoms selected from sulfur, oxygen and nitrogen or is a 6-membered aromatic ring which includes one to three  
 15 nitrogen atoms, wherein the heteroaryl is attached at carbon and may bear one or more methyl substituents on carbon or nitrogen).

2. A compound of Claim 1 wherein

20 Q<sup>1</sup> is phenyl or 2-naphthalenyl either of which may bear a chloro substituent;

L<sup>1</sup> is a direct bond or trans-ethen-1,2-diyl; and

Q<sup>2</sup> is Q<sup>2A</sup>, Q<sup>2B</sup>, or Q<sup>2C</sup> in which

25 Q<sup>2A</sup> is 4-piperidinyl which bears at the 1-position the group R;


Q<sup>2B</sup> is 1-piperazinyl which bears at the 4-position the group R; and

Q<sup>2C</sup> is 3,4-didehydropiperidin-4-yl which bears at the 1-position the group R;

30 R is  $-CHRYR^2$  or  $-CHRW^RX$  wherein

- 42 -

each of  $R^W$  and  $R^X$  independently is hydrogen or (1-3C)normal alkyl; or  $-CHR^WR^X$  is 2-indanyl or (showing the nitrogen to which it is attached) is



5

in which T is a single bond or methylene and U is methylene, ethylene, oxy,  $-S(O)_q-$  (wherein q is 0, 1 or 2) or imino (which may bear a methyl substituent), or T is  
 10 ethan-1,1-diyl and U is a single bond or methylene;  
 RY is hydrogen or methyl; and  
 RZ is isopropyl, t-butyl, (3-6C)cycloalkyl, phenyl (which is unsubstituted or bears one or more substituents independently selected from halo, methyl, methoxy and  
 15 hydroxy), 4-quinoliny1 or heteroaryl (which heteroaryl is a 5-membered aromatic ring which includes one to four heteroatoms selected from sulfur, oxygen and nitrogen or is a 6-membered aromatic ring which includes one to three nitrogen atoms, wherein the heteroaryl is attached at carbon  
 20 and may bear one or more methyl substituents on carbon or nitrogen).

3. The compound of Claim 1 or 2 wherein halo is fluoro, chloro, bromo or iodo; (1-3C)normal alkyl is methyl,  
 25 ethyl or propyl; and (3-6C)cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

4. The compound of any of Claims 1-3 wherein  $Q^1$  is 4-chlorophenyl or 6-chloronaphthalen-2-yl.

30

- 43 -

5. The compound of any of Claims 1-4 wherein  $-L^1-Q^1$  is 4-chloro-trans-styryl or 6-chloronaphthalen-2-yl.

6. The compound of any of Claims 1-5 wherein  $Q^2$  is  
5 1-isopropylpiperidin-4-yl, 1-cyclohexylpiperidin-4-yl,  
4-isopropylpiperazin-1-yl, or 1-(tetrahydropyran-4-yl)-  
piperidin-4-yl.

7. The pharmaceutically acceptable salt of a compound  
10 of formula I as claimed in any of Claims 1-6 which is an  
acid-addition salt made from a basic compound of formula I  
and an acid which provides a pharmaceutically acceptable  
anion.


8. A pharmaceutical formulation comprising in  
15 association with a pharmaceutically acceptable carrier,  
diluent or excipient, a novel compound of formula I (or a  
pharmaceutically acceptable salt thereof) as provided in any  
of Claims 1-7.

20

9. A process for preparing a compound of formula I  
(or a pharmaceutically acceptable salt thereof) as provided  
in Claim 1 which is selected from

(A) acylating an amine of formula II,


25



using a corresponding acid of formula  $HO-CO-Q^2$ , or an  
activated derivative thereof;

30 (B) for a compound of formula I in which  $Q^2$  is  $Q^{2B}$ ,  
acylating a pyrazine of formula  $H-Q^{2B}$  using an activated  
derivative of an acid of formula III,

- 44 -



(C) for a compound of formula I in which R is -CHRYR<sup>Z</sup>  
 5 or -CHR<sup>W</sup>R<sup>X</sup>, alkylating the amino nitrogen of a corresponding  
 compound of formula I in which R is hydrogen using an  
 alkylating agent of formula Y-CHRYR<sup>Z</sup> or Y-CHR<sup>W</sup>R<sup>X</sup> or  
 reductively alkylating the amine using a compound of formula  
 RY-CO-R<sup>Z</sup> or R<sup>W</sup>-CO-R<sup>X</sup>;

10       whereafter, for any of the above procedures, when a  
 functional group is protected using a protecting group,  
 removing the protecting group;

      whereafter, for any of the above procedures, when a  
 pharmaceutically acceptable salt of a compound of formula I  
 15 is required, it is obtained by reacting the basic form of a  
 basic compound of formula I with an acid affording a  
 physiologically acceptable counterion or the acidic form of  
 an acidic compound of formula I with a base affording a  
 physiologically acceptable counterion or by any other  
 20 conventional procedure;

      and wherein, unless otherwise specified, Q<sup>1</sup>, L<sup>1</sup> and Q<sup>2</sup>  
 have any of the values defined in Claim 1.

10. A method of inhibiting factor Xa comprising  
 25 administering to a mammal in need of treatment, a compound  
 of formula I as provided in any of Claims 1-7.

11. The use of a factor Xa inhibiting compound of  
 formula I substantially as hereinbefore described with  
 30 reference to any of the examples.

- 45 -

12. A novel compound of formula I substantially as hereinbefore described with reference to any of the examples.

- 5        13. A process for preparing a novel compound of formula I substantially as hereinbefore described with reference to any of the examples.



# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 99/29834

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D211/62 A61K31/445 C07D401/06 C07D405/04 C07D409/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 097 630 A (KABIVITRUM AB) 4 January 1984 (1984-01-04) claims -----	1,7,11

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 May 2000

Date of mailing of the international search report

23/05/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 29834

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 10  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/29834

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 97630 A	04-01-1984	AT 22882 T	15-11-1986
		DE 3366917 D	20-11-1986
		JP 59031757 A	20-02-1984
		US 4537896 A	27-08-1985
<hr/>			